Clinical and laboratory features of patients in the LUMINA cohort as a function of the occurrence of hypertension any time after enrollment into the LUMINA cohort
| Variables | Hypertension | p Value | |
|---|---|---|---|
| Present, (n = 136) | Absent, (n = 243) | ||
| LDL, low-density lipoprotein; NSAID, non-steroidal anti-inflammatory drugs. | |||
| *As per the Systemic Lupus Activity Measure-Revised over time, scores from the renal domain and hypertension were excluded. | |||
| †As per the Systemic Lupus International Collaborating Clinics Damage Index, scores from the renal domain were excluded. | |||
| Acute onset type (%) | 84 | 87 | 0.285 |
| Mean (SD) follow-up time, (years) | 2.6 (2.4) | 3.0 (2.5) | 0.112 |
| Mean (SD), total disease duration, (years) | 4.1 (2.9) | 4.2 (3.0) | 0.716 |
| Mean (SD) disease activity* | 8.0 (3.8) | 7.1 (4.2) | 0.046 |
| Mean (SD) damage accrual† | 0.6 (0.9) | 0.5 (1.0) | 0.337 |
| Renal involvement (%) | 62 | 30 | <0.001 |
| Diabetes mellitus (%) | 6 | 2 | 0.032 |
| Body mass index (kg/m2) | 26.4 (4.8) | 25.3 (4.5) | 0.026 |
| Mean (SD) baseline serum creatinine, (mg/dl) | 0.7 (0.4) | 0.7 (0.3) | 0.307 |
| Mean (SD) LDL cholesterol, (mg/dl) | 99 (38) | 94 (39) | 0.193 |
| LDL cholesterol >130 mg/dl (%) | 20 | 12 | 0.061 |
| Mean (SD) triglyceride, (mg/dl) | 133 (69) | 122 (66) | 0.152 |
| Mean (SD) high sensitivity- C reactive protein | 13.3 (21.9) | 12.2 (30.3) | 0.712 |
| Anti-dsDNA antibodies (%) | 57 | 47 | 0.070 |
| Antiphospholipid antibodies (%) | 34 | 22 | 0.014 |
| Low-dose aspirin use (%) | 11 | 17 | 0.102 |
| Use of NSAID (%) | 56 | 57 | 0.864 |
| Hydroxychloroquine use (%) | 85 | 86 | 0.762 |
| Glucocorticoid use (%) | 96 | 89 | 0.035 |
| Weighted average glucocorticoid dose (in mg of prednisone/day) | 7.1 (10.3) | 6.7 (11.7) | 0.738 |